Optimizing Exposure Therapy for Anxiety Disorders

Panic Disorder Clinical Trial

— OptEx  

Official title:

Inhibitory Learning vs. Habituation: Models of Exposure Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04048824
• Other study ID #: Optimizing Exposure
• Status: Recruiting
• Phase: N/A
• Start date: August 14, 2015
• Est. completion date: June 1, 2024

Study information

• Verified date: March 2024
• Source: University of California, Los Angeles
• Contact: Julian Ruiz, BA
• Phone: (562) 459-4938
• Email: jruiz[@]psych.ucla.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will compare the effects that two different approaches of exposure therapy have on reducing fear and anxiety in individuals with social anxiety disorder or panic disorder.

Description:

A substantial number of individuals fail to achieve clinically significant symptom relief from exposure-based therapies or experience a return of fear following exposure therapy completion. The prevailing model of exposure therapy for phobias and anxiety disorders purports that fear reduction throughout exposure therapy (i.e., habituation) is reflective of learning and critical to overall therapeutic outcome. However, the amount by which fear - indexed by both self-report, behavioral, and biological correlates of fear expression - reduces by the end of an exposure trial or series of exposure trials is not a reliable predictor of the fear level expressed at follow-up assessment.

Developments in the theory and science of fear extinction, and learning and memory, indicate that 'performance during training' is not commensurate with learning at the process level. Inconsistent findings regarding fear reduction are paralleled by findings based in associative learning laboratory paradigms with animals and human samples, specifically that outward expression of fear on the one hand, and conditional associations indicative of underlying learning on the other hand, may not always change in concordance. Rather, 'inhibitory learning' is recognized as being central to extinction, rather than fear during extinction training.

The current proposal will compare the habituation-based model of exposure therapy to the competing inhibitory model of exposure that emphasizes learning theory principles.

The current study plans to recruit participants for a treatment trial consisting of two psychotherapies: (a) habituation-based exposure therapy and (b) inhibitory learning-based exposure therapy. The primary goal of this study is to determine if one theoretical approach to exposure outperforms the other in reducing symptoms.

This study is conducted with individuals meeting diagnostic criteria for social anxiety disorder or panic disorder. Participants will be randomized to either treatment condition and receive 9 sessions of individual psychotherapy focused on either of these disorders. If individual meets diagnostic criteria for both disorders, treatment will be focused on the primary presenting disorder. Participants will complete four assessments over the course of the study, at pre-treatment, mid-treatment, post-treatment, and three-month follow-up. Pre-treatment, mid-treatment, and post-treatment assessments occur over two days, while three-month follow-up requires only a single day and is conducted remotely.

These assessments will include semi-structured interviews, self-report questionnaires, and laboratory paradigms designed to examine fear learning processes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: June 1, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Seeking treatment for social anxiety or panic disorder and demonstration of elevated scores using standardized self-report measures and diagnostic interview

2. Age 18 to 65

3. Either stabilized on psychotropic medications or medication-free

4. English-speaking

5. Access to telehealth resources (for Zoom treatment sessions after March 2020 due to COVID-19)

Exclusion criteria include:

1. Patient report of serious medical conditions - such as respiratory (e.g., chronic obstructive pulmonary disease), cardiovascular, pulmonary, neurological, muscular-skeletal diseases - or pregnancy

2. Active suicidal ideation or self-harm in the past year; history of suicide attempts in the last 10 years

3. History of bipolar disorder, psychosis, mental retardation or organic brain damage

4. Substance abuse/dependence within last 6 months

5. Concurrent therapy focused on anxiety. Participants are allowed to be in other forms of therapy, provided the therapy does not focus on anxiety (e.g., supportive counseling) and they have been stabilized on this alternative therapy for at least 6 months

Related Conditions & MeSH terms

• Anxiety Disorders
• Panic Disorder
• Phobia, Social
• Social Anxiety Disorder

Intervention

Behavioral:
• Inhibitory Learning-Based Exposure
9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
• Habituation-Based Exposure
9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.

Locations

Country	Name	City	State
United States	University of California, Los Angeles	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in clinician-rated severity of social anxiety or panic disorder	Clinician severity rating (0-8) of social anxiety or panic disorder using the Structured Clinical Interview for DSM-5 (SCID-5).	Pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)
Primary	Change in self-reported symptom severity of social anxiety or panic disorder	Self-reported symptom severity of social anxiety disorder using the Liebowitz Social Anxiety Scale (LSAS) or panic disorder using the Panic Disorder Severity Scale-Self Report (PDSS-SR).	Pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)
Secondary	Change in fear extinction generalization as measured by expectancy of unconditional stimuli during conditional stimuli presentation.	Change in responsiveness to fear generalized from various, perceptually similar stimuli collected during a laboratory fear paradigm.	Pre-treatment to post-treatment (9 weeks)
Secondary	Change in fear extinction generalization as measured by skin conductance.	Change in skin conductance to fear generalized from various, perceptually similar stimuli collected during a laboratory fear paradigm. (Discontinued March 2020 due to COVID-19)	Pre-treatment to post-treatment (9 weeks)
Secondary	Change in fear extinction generalization as measured by heart rate.	Change in heart rate to fear generalized from various, perceptually similar stimuli collected during a laboratory fear paradigm. (Discontinued March 2020 due to COVID-19)	Pre-treatment to post-treatment (10 weeks)
Secondary	Implicit Fear Association Test	Change in implicit associations for fear-relevant word stimuli	Pre-treatment to post-treatment (10 weeks)
Secondary	Behavioral Avoidance Test (BAT)	Change in duration and subjective fear of public speaking in situ	Pre-treatment to post-treatment (10 weeks)
Secondary	Probability and Cost Questionnaire	Change in perceived likelihood and perceived consequence of fear-relevant outcomes	Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
Secondary	Anxiety Sensitivity Index (ASI-3)	Change in appraisal of harmfulness of symptoms	Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
Secondary	Positive and Negative Affect Schedule (PANAS 20 item)	Change in affect	Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
Secondary	Panic Disorder Severity Scale-Self Report (PDSS-SR)	Change in panic disorder symptoms	Weekly throughout the duration of treatment (10 weeks) and once at follow-up (24 weeks)
Secondary	Sheehan Disability Scale (SDS)	Change in functioning related to mental health	Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
Secondary	Mini-SPIN	Change in social anxiety symptoms. Scores on the Mini-SPIN range from 0 to 12 with higher scores indicating higher social anxiety severity.	Weekly throughout the duration of treatment (10 weeks) and once at follow-up (24 weeks)